Immunotherapy-boosted chemo shows striking early results against high-risk nasopharyngeal cancer

Nasopharyngeal carcinoma has always been a disease of geography. It clusters in southern China, Southeast Asia, and parts of North Africa, where Epstein–Barr virus infection, dietary factors, and genetic background combine to make it one of the most common head and neck cancers. But in the non-endemic regions of China—areas far from the disease’s traditional heartland—patients with this tumor face a different reality: later diagnoses, thinner clinical trial coverage, and treatment standards borrowed from studies conducted in populations very different from their own. A new prospective phase II pilot study, published in BMC Cancer, now offers the first dedicated evidence from one of these overlooked regions, and the early numbers are turning heads.

The trial, conducted at the Second People’s Hospital of Neijiang in Sichuan Province between January 2022 and December 2023, tested a strategy that layers modern immunotherapy onto the established backbone of nasopharyngeal cancer care. Twenty-two patients with high-risk, non-metastatic disease were enrolled, all classified according to the American Joint Committee on Cancer 8th edition staging system as either T4N0–3M0 or T1–4N3M0. In plain terms, these were patients whose tumors had either invaded deep structures of the skull base and surrounding tissues or had spread extensively to the lymph nodes of the neck—the two features that most reliably predict treatment failure with standard therapy alone.

The treatment sequence followed a logic familiar to head and neck oncologists but with a critical addition. All patients first received three cycles of induction chemotherapy combining gemcitabine and cisplatin—the standard GP regimen—with tislelizumab, a monoclonal antibody that blocks the programmed cell death protein 1, or PD-1, receptor on T cells. By inhibiting this immune checkpoint, tislelizumab prevents tumor cells from switching off the cytotoxic T lymphocytes that would otherwise destroy them, effectively releasing the brakes on the body’s own anti-cancer immune response. Nasopharyngeal carcinoma is particularly suited to this approach because it is an Epstein–Barr virus-associated tumor, rich in PD-L1 expression and infiltrated with immune cells, making it one of the more immunologically hot solid malignancies.

After induction, patients moved on to concurrent chemoradiotherapy, the historical cornerstone of treatment for locally advanced disease. Radiation was delivered using volumetric modulated arc therapy, a technique that shapes multiple rotating beam arcs around the tumor while sparing the salivary glands, spinal cord, and brainstem. The planning target volumes were defined with MRI and CT fusion imaging, distinguishing the gross tumor volume of the primary nasopharyngeal lesion from that of involved cervical lymph nodes, and ensuring that 95 percent of each target volume received the prescribed dose—a metric known as D95 that reflects the homogeneity of radiation delivery.

The response data after the induction phase alone were remarkable. Among the 21 patients who actually received study treatment, the objective response rate for primary nasopharyngeal tumors was 95.2 percent, with 33.3 percent achieving complete disappearance of detectable disease and 61.9 percent showing partial shrinkage. Even more striking, the response rate in cervical lymph nodes was 100 percent, with 23.8 percent complete responses and 76.2 percent partial responses. These figures were assessed using standard Response Evaluation Criteria in Solid Tumors, the internationally recognized framework for measuring tumor burden on imaging.

Following the completion of concurrent chemoradiotherapy, the complete response rate climbed to 100 percent for primary lesions and 95.2 percent for cervical lymph nodes. In other words, by the end of the full treatment sequence, every patient had achieved complete eradication of their primary tumor on imaging, and all but one had cleared their nodal disease as well. For a cohort selected specifically because of its high-risk features, this level of tumor control represents a signal that demands attention from the broader oncology community.

Survival outcomes, estimated using the Kaplan–Meier method with a median follow-up of 37.9 months, reinforced this preliminary enthusiasm. The 36-month event-free survival rate—the primary endpoint of the study—was 80.0 percent, with 10 patients remaining at risk at the 36-month landmark. Event-free survival captures not just whether the cancer returns, but whether patients experience any of a defined set of adverse events including locoregional recurrence, distant metastasis, or death from any cause. The 36-month locoregional recurrence-free survival rate was 90.5 percent, the distant metastasis-free survival rate was 94.4 percent, and the overall survival rate was 95.2 percent. These numbers sit comfortably alongside, and in some respects exceed, what has been reported from larger trials conducted in endemic regions.

Safety was a critical question for a regimen that combines cytotoxic chemotherapy, radiation, and immune checkpoint blockade simultaneously. The most common toxicities observed were hematologic events—drops in blood cell counts—gastrointestinal side effects such as nausea and vomiting, and radiation-related oral mucositis and dermatitis, the expected inflammatory damage to the lining of the mouth and skin of the neck that accompanies high-dose head and neck radiotherapy. Crucially, no patient discontinued treatment because of immune-related adverse events, the category of toxicity unique to checkpoint inhibitors that can include pneumonitis, colitis, hepatitis, and endocrinopathies. This finding suggests that adding tislelizumab to the induction phase did not amplify the immune toxicity burden beyond what the concurrent chemoradiotherapy phase already imposed.

One patient withdrew before treatment initiation because of rapid disease progression and renal dysfunction and did not receive study treatment, leaving 21 patients in the treated and safety populations. The trial was registered with the Chinese Clinical Trial Registry as ChiCTR2300078941, though the registration date of 21 December 2023 means it was retrospectively registered—a limitation the authors acknowledge. The study was supported by the Sichuan Anti-cancer Association Clinical Research Project and received ethics approval from the Medical Ethics Committee of the Second People’s Hospital of Neijiang City, with written informed consent obtained from all participants in accordance with the Declaration of Helsinki.

The authors are careful to frame this as an exploratory pilot study rather than a practice-changing trial. Twenty-one patients from a single center cannot establish a new standard of care, and the absence of a concurrent control arm means the contribution of tislelizumab specifically—rather than the GP chemotherapy backbone or the radiation itself—cannot be isolated from these data alone. Nevertheless, the consistency of the response rates, the durability of the survival figures at three years, and the clean safety profile collectively argue that this strategy deserves evaluation in larger, prospective, randomized controlled trials. For patients with high-risk locally advanced nasopharyngeal carcinoma in non-endemic regions of China and beyond, where clinical evidence has historically been thinnest, this study provides a first concrete signal that adding PD-1 blockade to induction chemotherapy may meaningfully improve outcomes in the populations that need it most.

Subject of Research: Oncology

Article Title: Tislelizumab plus gemcitabine–cisplatin induction chemotherapy followed by concurrent chemoradiotherapy for high-risk locally advanced nasopharyngeal carcinoma in a non-endemic region of China: a prospective single-center pilot phase II study

Article References: Li, H., Li, Y., Lin, F., Ye, Z., Wang, Y., Liu, G., Li, N., Mou, X., Cai, M., Li, B., You, Y., Liu, X., Liu, Y., & Liu, L. (2026). Tislelizumab plus gemcitabine–cisplatin induction chemotherapy followed by concurrent chemoradiotherapy for high-risk locally advanced nasopharyngeal carcinoma in a non-endemic region of China: a prospective single-center pilot phase II study. BMC Cancer. https://doi.org/10.1186/s12885-026-16702-y

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16702-y

Keywords: Tislelizumab, plus, gemcitabine, cisplatin, induction, chemotherapy, followed, concurrent, chemoradiotherapy, high-risk, locally, advanced